If the patient is using insulin temporarily (e.g., for short-term inpatient management), do not assign Z79.4
Phase 2 trial data (published in the New England Journal of Medicine, 2023) have demonstrated significant weight loss and improvements in glycaemic markers, but the complete safety profile including the precise risk of low blood sugar continues to be characterised
Understanding what to expectfrom common gastrointestinal side effects like nausea and bloating to early appetite suppressioncan help you navigate this adjustment period with confidence
2023 Sep Koutatsu Maruyama, Ehab S Eshak, Minako Kinuta, Masanori Nagao, Renzhe Cui, Hironori Imano, Tetsuya Ohira, Hiroyasu Iso
Low B12 is more common than many people realise